Lobe Sciences Ltd · CSE:LOBE
Lobe Sciences — Investor Presentation (September 2026)
29 slides from Lobe Sciences's investor presentation, Sep 15, 2026
Slide 1: A Pharmaceutical Development Platform with two clinical stage assets
A Pharmaceutical Development Platform with two clinical stage assets: • L-130 a stabilized psilocin with several ongoing applications • S-100 for the treatment of sickle cell disease September 15, 2026 Dr. Frederick D. Sancilio, PhD — CEO & Chairman CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F
Slide 2: Disclaimer
Disclaimer • This presentation (“Presentation”) is an update of Lobe Sciences, Inc. (the “Company”) and is for information purposes only and should not be relied on for the purposes of making an investment decision. This Presentation does not, and it is not intended to, provide any financial, legal,
Slide 3: Lobe Operates Three Therapeutically focused Subsidiaries
Lobe Operates Three Therapeutically focused Subsidiaries This presentation will focus on Cynaptec’s L-130 (psilocin mucate) CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 3
Slide 4: Psilocybin Development Landscape
Psilocybin Development Landscape Most programs use episodic, medically monitored dosing sessions — not a daily outpatient rug model LobeSciences Treatment-session model One or two high-dose sessions, then follow-up for weeks or months rather than daily self-administration. Monitoring burden Controll
Slide 5: Psilocybin is an Inactive Prodrug and must be Dephosphorylated to Psilocin
Psilocybin is an Inactive Prodrug and must be Enzymatically Dephosphorylated to become Psilocin; the Active Metabolite 52% (20% - 80%)
Slide 6: Current Challenges Facing the Development of Psilocybin as a Therapeutic
Current Challenges Facing the Development of Psilocybin as a Therapeutic Psilocybin is a Prodrug which Psilocybin is poorly bioavailable To provide consistent therapeutic must be metabolized to Psilocin (50%) and inconsistent effect, dose levels must be higher to be active than needed causing severe
Slide 7: The Problem and the Solution: Psilocybin Psilocin
The Problem and the Solution: Psilocybin Psilocin Problem: Dosing psilocybin at • The hallucinations force the use of the therapeutic to be infrequent (weekly or levels that will be consistently less frequent dosing interval) efficacious require doses that • Patients have to be observed for hours po
Slide 8: Psilocin Degradation Pathways
Psilocin Degradation Pathways Unprotected (Free Base) Oxidation (phenol — quinone) N-Oxidation (tertiary amine) Labile O° CH. site 1 o fi 3 (phenolic 4-OH) ged “cH; | prs HO. “cH, 0» 5} dirali HO. N H,0. N ae SCitag a8 ee r Labile A \ (oxidants) H site 2 Psilocinquinone N a RaNRee (tertiary amine) (
Slide 9: The Solution to Psilocybin's Challenges: L-130 (Psilocin Mucate)
The Solution to Psilocybin’s Challenges: L-130 (Psilocin Mucate) Delivers psilocin the active metabolite as a stable API Following 129 attempts to stabilize psilocin, the mucate (L-130) was synthesized CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 10
Slide 10: L-130 (Psilocin Mucate Salt)
L-130 (Psilocin Mucate Salt) Single-Molecule Interaction Model io) Protonated amine (NH*(CHs)2) 7 ‘a eC |_ Mucate anion (trans,trans-mucate, 2—) Psilocin (protonated ane J ral va Phenolic 4-OH Indole N-H (no interaction)
Slide 11: Can Psilocin be given daily, at sub-hallucinogenic levels and still be effective?
Can Psilocin be given daily, at sub-hallucinogenic levels and still be effective? Four independent preclinical assessments were made comparing daily versus weekly dosing. Animals were subjected to stress (CUMS*) then the impact of a human equivalent dose of ~2mg was measured as follows: • Cortisol L
Slide 12: Cortisol Levels Following CUMS (n=60)
Cortisol Levels Following CUMS (n=60) Only Daily Dosing Results are Statistically Significant CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 13
Slide 13: Elevated Plus Maze (n=60)
Elevated Plus Maze (n=60) Only Daily Dosing Results were Statistically Significant CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 14
Slide 14: Open Field-Internal Zone (n=60)
Open Field-Internal Zone (n=60) Only Daily Dosing Resulted in Statistical Significance CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 15
Slide 15: Novel Object Recognition (n=60)
Novel Object Recognition (n=60) • Both Daily (G4) and Weekly(G5) achieved significant results • However, daily dosing results were nearly identical to those observed for the naïve group CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F 16
Slide 16: A Repeat Dose Study Assessing Potential Hallucinations at 3 Dose Levels
A Repeat Dose Study Assessing Potential LobeSciences Hallucinations at 3 Dose Levels Head-twitch response (HTR) across repeat dosing, highlighting Day 1 and Day 7. Key observations (p-values appear in charts): • At doses at and above that which showed efficacy in the anxiety studies, HTR was not dif
Slide 17: L-130 Psilocin Mucate's First-In-Human Study
L-130 Psilocin Mucate’s “First-In-Human” Study Published: Sancilio et al., 2024 Study Design • Single-dose Phase 1a safety study (4 mg psilocin mucate) Safety • No serious adverse events and no hallucinogenic effects at this dose Pharmacokinetics • Psilocin was rapidly absorbed after oral administra
Slide 18: Human Psilocin Exposure (Psilocybin vs Psilocin)
Human Psilocin Exposure (Psilocybin vs Psilocin) LobeSciences Psilocin derived from psilocybin shows broad variability; L-130 psilocin mucate shows a tighter exposure range. L-130 appears to deliver psilocin more efficiently and far more reproducibly than psilocybin, potentially enabling predictable
Slide 19: L-130 Appears Active in Anxiolytic Models and Shows Similar Signs in Humans
L-130 Appears Active in Anxiolytic Models and Shows Similar Signs in Humans with no Hallucinations Any application utilizing psilocybin can be easily reformulated with psilocin (L-130) Psilocin (L-130) has demonstrated superior anxiolytic activity (preclinical) given daily compared to weekly dosing
Slide 20: Current Applications of L-130 (psilocin mucate)
Current Applications of L-130 (psilocin mucate) = A Patented and New Chemical Entity and some Applications LobeSciences Cluster Headache (CH): Targeting one of the most severe pain conditions known, affecting 200,000+ in the U.S. and over one million globally. An unmet need. Substance Use Disorder (
Slide 21: Applied Lipid Technologies, Inc.
Applied Lipid Technologies, Inc. Applied Lipid Technologies, Inc. is a clinical-stage subsidiary focused on the treatment of membranopathies. Current programs include the treatment of pediatric sickle disease. Additional investigation into other rare conditions such as cystic fibrosis are being expl
Slide 22: Introducing S-100: A Treatment Of Sickle Cell Disease
Applied Lipid Introducing S-100: Technologies, Inc. A Treatment Of Sickle Cell Disease Sickle Cell Disease (SCD): Over 100,000 patients in the U.S. Current drugs marginally effective with significant side effects and compliance issues. Pfizer’s approved drug (acquired for >$5BB) was withdrawn for sa
Slide 23: Red Blood Cell Membrane Fatty Acids
Red Blood Cell Membrane Fatty Acids Balanced membrane Sickle cell disease membrane (delivered as eDHAEE — emulsified DHA ethyl ester) $ DHA ; Arachidonic acid (AA) & RBC adhesion proteins (e.g., BCAM/Lu, ICAM-4) e@ Pro-inflammatory mediators (e.g., cytokines)
Slide 24: The SCD Membrane-Depletion Hypothesis
The SCD Membrane-Depletion Hypothesis A link between oxidative stress, membrane composition and disease activity 1. Published observation SCD is associated with depleted membrane DHA/EPA, a higher pro-inflammatory AA- to-omega-3 balance, abnormal adhesion biology and chronic inflammation. 2. Propose
Slide 25: The SCOT Trial: Rapid Membrane Delivery
The SCOT Trial: Rapid Membrane Delivery eDHAEE Allowed Replenishment of Membrane DHA levels with Minimal Capsules/dose Rapid membrane enrichment (SCOT) At Week 4, blood-cell membrane DHA+EPA increased 109%, 164% and 171% at 20, 36 and 60 mg DHA/kg/day. The 36- and 60-mg doses were significant versus
Slide 26: Annualized Rate of VOCs
Applied Lipid Vaso-occlusive Crisis (VOC) Data After 8 Weeks Technologies, Inc. Of Treatment With Docosahexaenoate (DHAEE) Active (N = 50) Placebo (N = 17) 4 3.46 3.45 3.5 3.35 Annualized Rate of VOCs 3 24% 40% 2.5 1.96 2 1.5 76% 1 60% 0.5 0 Baseline Double Blind (Week 8) Baseline Double Blind (Week
Slide 27: Vaso-occlusive Crisis in Patients Treated With Ethyl Docosahexaenoate
Applied Lipid Vaso-occlusive Crisis (VOC) In Patients Technologies, Inc. Treated With Ethyl Docosahexaenoate ≥370 Days Exposure (N=37*) 140 38.95% reduction observed 120 at Day 370 100 21.62% of patients (8 of 37) 80 were crisis free at Day 370 60 40 Expected VOC’s calculated using annualized rate 2
Slide 28: Pipeline and Development Timeline
Lobe Sciences Cynaptec PIPELINE AND DEVELOPMENT TIMELINE Conjugated Psilocin™ (L-130) A novel, stabilized psilocin-based therapeutic platform designed for non-hallucinogenic, repeat dosing across multiple neuropsychiatric indications. Program / Indication Conjugated ——_ Headache (CCH) a TT (L-1 30)
Slide 29: Thank You
Thank You Dr. Frederick D. Sancilio, PhD CEO & Chairman lobesciences.com CSE: LOBE • OTCQB: LOBEF • FSE: LOBE.F
Lobe Sciences — Investor Presentation (September 2026) on 6ix